Mass cytometry uncovers distinct blood myeloid phenotypes linked to clinical responses during gastric cancer chemoimmunotherapy - PubMed

4 hours ago

Combination of immune checkpoint inhibitors (ICIs) and chemotherapy improves outcomes in metastatic gastric cancer (GC).
Mass cytometry analysis of blood samples from GC patients undergoing pembrolizumab plus XELOX therapy revealed changes in immune cell subsets.
Increased natural killer cells and myeloid cell subsets were observed during chemoimmunotherapy.
Higher proportions of monocytes in PBMCs at early chemotherapy stage (FU1) correlated with better clinical response and survival.
Monocytes showed similarities to monocyte-derived M1-like macrophages found in tumor tissue, indicating tumor infiltration post-chemotherapy.
Gene expression analysis in responders showed upregulation of chemokines CXCL8, CCL3, and CCL4 at FU1.
After adding pembrolizumab, memory CD8 T cells increased in responders compared to non-responders.
Early changes in blood myeloid cells, especially monocytes, can serve as biomarkers for assessing clinical response to chemoimmunotherapy in gastric cancer.

Hasty Briefsbeta